Meloxicam

Meloxicam
Clinical data
Trade namesMobic, others
AHFS/Drugs.comMonograph
MedlinePlusa601242
License data
Pregnancy
category
Routes of
administration
By mouth, intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability89%[7]
Protein binding99.4%[7]
MetabolismLiver (CYP2C9 and 3A4-mediated)[7]
Elimination half-life20 hours[7]
ExcretionUrine and feces equally[7]
Identifiers
  • 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard100.113.257 Edit this at Wikidata
Chemical and physical data
FormulaC14H13N3O4S2
Molar mass351.40 g·mol−1
3D model (JSmol)
  • Cc1cnc(s1)NC(=O)C\3=C(/O)c2ccccc2S(=O)(=O)N/3C
  • InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18H,1-2H3,(H,15,16,19) checkY
  • Key:ZRVUJXDFFKFLMG-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Meloxicam, sold under the brand name Mobic among others, is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation in rheumatic diseases and osteoarthritis.[8][9] It is used by mouth or by injection into a vein.[9][10] It is recommended that it be used for as short a period as possible and at a low dose.[9]

Common side effects include abdominal pain, dizziness, swelling, headache, and a rash.[9] Serious side effects may include heart disease, stroke, kidney problems, and stomach ulcers.[9] Use is not recommended in the third trimester of pregnancy.[9] It blocks cyclooxygenase-2 (COX-2) more than it blocks cyclooxygenase-1 (COX-1).[9] It is in the oxicam family of chemicals and is closely related to piroxicam.[9]

Meloxicam was patented in 1977 and approved for medical use in the United States in 2000.[9][11] It was developed by Boehringer Ingelheim; however, it is also available as a generic medication.[9] In 2021, it was the 32nd most commonly prescribed medication in the United States, with more than 18 million prescriptions.[12][13] An intravenous version of meloxicam (Anjeso) was approved for medical use in the United States in February 2020.[14][10]

  1. ^ Use During Pregnancy and Breastfeeding
  2. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
  3. ^ "Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Retrieved 25 March 2024.
  4. ^ "Mobic- meloxicam tablet". DailyMed. Retrieved 15 May 2021.
  5. ^ "Anjeso- meloxicam injection". DailyMed. Retrieved 15 May 2021.
  6. ^ "Loxitab EPAR". European Medicines Agency. 8 September 2023. Retrieved 24 May 2024.
  7. ^ a b c d e Cite error: The named reference drugs1996 was invoked but never defined (see the help page).
  8. ^ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 1112–1113. ISBN 9780857113382.
  9. ^ a b c d e f g h i j "Meloxicam Monograph for Professionals". Drugs.com. AHFS. Archived from the original on 23 December 2018. Retrieved 23 December 2018.
  10. ^ a b Cite error: The named reference Anjeso PR was invoked but never defined (see the help page).
  11. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 519. ISBN 9783527607495. Archived from the original on 10 July 2020. Retrieved 30 June 2020.
  12. ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
  13. ^ "Meloxicam - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
  14. ^ "Anjeso- meloxicam injection". DailyMed. 22 February 2022. Retrieved 8 October 2022.

© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search